User contributions
Jump to navigation
Jump to search
- 13:05, 4 May 2024 diff hist +151 m Rhabdomyosarcoma →All lines of therapy current
- 13:03, 4 May 2024 diff hist +291 m Rhabdomyosarcoma →VA {{#subobject:a9710b|Regimen=1}}
- 01:10, 4 May 2024 diff hist +74 m Hereditary hemorrhagic telangiectasia - null regimens current
- 01:09, 4 May 2024 diff hist -18 m Hereditary hemorrhagic telangiectasia →Tranexamic acid monotherapy {{#subobject:ea894c|Regimen=1}} current
- 01:07, 4 May 2024 diff hist +44 m Hereditary hemorrhagic telangiectasia →References
- 01:06, 4 May 2024 diff hist +268 m Hereditary hemorrhagic telangiectasia →Tranexamic acid monotherapy {{#subobject:ea894c|Regimen=1}}
- 01:01, 4 May 2024 diff hist +148 m Hereditary hemorrhagic telangiectasia →Tamoxifen monotherapy {{#subobject:b1894c|Regimen=1}}
- 00:59, 4 May 2024 diff hist +152 m Hepatoblastoma →Neoadjuvant therap current
- 00:57, 4 May 2024 diff hist +2,484 m Hepatoblastoma →Adjuvant therapy
- 00:56, 4 May 2024 diff hist -2,461 m Hepatoblastoma →Cisplatin monotherapy {{#subobject:ea894c|Regimen=1}}
- 00:55, 4 May 2024 diff hist +58 m Hepatoblastoma →COG AHEP0731 protocol H - non-responders {{#subobject:3a882f|Regimen=1}}
- 00:54, 4 May 2024 diff hist +4,683 Hepatoblastoma →SIOPEL-4 protocol {{#subobject:3a6ad9|Regimen=1}}
- 00:33, 4 May 2024 diff hist +66 m Follicular lymphoma - historical →ProMACE-MOPP {{#subobject:0aa31b|Regimen=1}} current
- 00:32, 4 May 2024 diff hist +55 m Breast cancer - historical →Methotrexate & Thiotepa {{#subobject:c67a88|Regimen=1}} current
- 23:53, 3 May 2024 diff hist +314 m Classical Hodgkin lymphoma - historical →ABVD {{#subobject:c5a35d|Regimen=1}} current
- 23:49, 3 May 2024 diff hist +70 m Classical Hodgkin lymphoma - historical →NOVP {{#subobject:230457|Regimen=1}}
- 23:44, 3 May 2024 diff hist +478 m Classical Hodgkin lymphoma - historical →COPP/ABVD {{#subobject:92a2c8|Regimen=1}}
- 23:40, 3 May 2024 diff hist +111 m B-cell acute lymphoblastic leukemia, pediatric - historical →L-Asparaginase, Vincristine, Prednisone {{#subobject:87ybf2|Regimen=1}} current
- 23:39, 3 May 2024 diff hist +246 m B-cell acute lymphoblastic leukemia, pediatric - historical →Daunorubicin & Prednisone {{#subobject:aa10e0|Regimen=1}}
- 23:35, 3 May 2024 diff hist +152 m B-cell acute lymphoblastic leukemia, pediatric - historical →Cyclophosphamide monotherapy {{#subobject:cd166d|Regimen=1}}
- 23:33, 3 May 2024 diff hist +392 m B-cell acute lymphoblastic leukemia, pediatric - historical →Daunorubicin, Vincristine, Prednisolone {{#subobject:h1huh5|Regimen=1}}
- 23:29, 3 May 2024 diff hist +256 m B-cell acute lymphoblastic leukemia, pediatric - historical →Daunorubicin, Vincristine, Prednisone {{#subobject:h1huh5|Regimen=1}}
- 20:50, 3 May 2024 diff hist +154 m Extranodal NK- and T-cell lymphoma, nasal type →DEP & RT {{#subobject:d8a9eb|Regimen=1}} current
- 20:46, 3 May 2024 diff hist +355 m Small cell lung cancer - historical →ICE {{#subobject:f535c2|Regimen=1}} current
- 20:43, 3 May 2024 diff hist +451 m Small cell lung cancer - historical →CC/DE & RT {{#subobject:189bcc|Regimen=1}}
- 20:33, 3 May 2024 diff hist -182 m Rhabdomyosarcoma, pediatric current
- 20:28, 3 May 2024 diff hist +1,399 m Classical Hodgkin lymphoma - historical →Untreated
- 20:27, 3 May 2024 diff hist -1,368 m Classical Hodgkin lymphoma →VEBEP {{#subobject:d7a2a6|Regimen=1}} current
- 20:21, 3 May 2024 diff hist +116 m Classical Hodgkin lymphoma →VEBEP {{#subobject:d7a2a6|Regimen=1}}
- 20:04, 3 May 2024 diff hist +3 m Endometrial cancer current
- 19:58, 3 May 2024 diff hist +549 m Classical Hodgkin lymphoma - historical →COPP/ABVD {{#subobject:92a2c8|Regimen=1}}
- 19:20, 3 May 2024 diff hist +137 m Prostate cancer current
- 18:59, 3 May 2024 diff hist +2,641 m Non-small cell lung cancer, squamous →Carboplatin & Paclitaxel (CP) {{#subobject:c5fbdf|Regimen=1}} current
- 18:54, 3 May 2024 diff hist +2,074 Non-small cell lung cancer, squamous →Carboplatin & Paclitaxel (CP) & Pembrolizumab {{#subobject:1dc8a3|Regimen=1}}
- 18:47, 3 May 2024 diff hist +2,076 m Hepatocellular carcinoma current
- 17:07, 3 May 2024 diff hist +55 m Medulloblastoma →Consolidation current
- 17:00, 3 May 2024 diff hist -24 m HIV-associated lymphoma →CNS therapy, prophylaxis {{#subobject:724xbj|Variant=1}} current
- 16:52, 3 May 2024 diff hist +11 m Ewing sarcoma, pediatric current
- 16:51, 3 May 2024 diff hist -80 m Ewing sarcoma, pediatric →COG AEWS1031 Regimen A
- 16:40, 3 May 2024 diff hist -25 m Burkitt lymphoma current
- 12:39, 3 May 2024 diff hist +523 m PJP Prophylaxis current
- 12:34, 3 May 2024 diff hist +33 m Cancer-related fatigue current
- 12:34, 3 May 2024 diff hist +33 m Cancer-related fatigue
- 12:26, 3 May 2024 diff hist +570 m Antidepressants and other psychiatric medications in cancer care current
- 12:22, 3 May 2024 diff hist +93 m Professional organizations current
- 10:57, 3 May 2024 diff hist +1,139 m Head and neck cancer →Cisplatin & RT {{#subobject:c7061f|Regimen=1}} current
- 10:45, 3 May 2024 diff hist +1,725 m Breast cancer, HER2-positive current
- 10:42, 3 May 2024 diff hist +1,080 m Cholangiocarcinoma current
- 01:26, 2 May 2024 diff hist -14 m Immunotherapy toxicity management current
- 01:26, 2 May 2024 diff hist +15 m Immunotherapy toxicity management →Guidelines
- 01:24, 2 May 2024 diff hist -2,558 m Immunotherapy toxicity management →Guidelines
- 01:04, 2 May 2024 diff hist +108 m Category:Guideline pages current
- 01:04, 2 May 2024 diff hist -8 m NCCN guidelines →Fatigue current
- 01:03, 2 May 2024 diff hist -8 m ESMO guidelines →Palliative care current
- 01:03, 2 May 2024 diff hist +36 N Category:Guideline pages Created page with "Category:General reference pages"
- 01:03, 2 May 2024 diff hist -8 m ASCO guidelines current
- 01:02, 2 May 2024 diff hist +32 m NCCN guidelines
- 01:01, 2 May 2024 diff hist -13 m ESMO guidelines
- 01:00, 2 May 2024 diff hist +2 m ASCO guidelines →Pain
- 01:00, 2 May 2024 diff hist +2 m ASCO guidelines
- 01:00, 2 May 2024 diff hist +28 m ASCO guidelines
- 00:05, 2 May 2024 diff hist +634 m Pyruvate kinase deficiency current
- 20:14, 1 May 2024 diff hist +3 m Ovarian cancer →Carboplatin, Pegylated liposomal doxorubicin, Bevacizumab {{#subobject:a38gbb|Regimen=1}} current
- 15:53, 1 May 2024 diff hist +6 m Nasopharyngeal carcinoma current
- 13:47, 1 May 2024 diff hist -167 m Breast cancer →AC-T {{#subobject:633n67|Regimen=1}} current
- 22:56, 30 April 2024 diff hist +209 m How I Treat →Waldenström macroglobulinemia (WM) current
- 22:54, 30 April 2024 diff hist +751 m Follicular lymphoma →References current
- 19:46, 30 April 2024 diff hist +1,008 m Breast cancer, HER2-positive
- 17:35, 30 April 2024 diff hist +1,912 Multiple myeloma, relapsed-refractory →VTD {{#subobject:96881b|Regimen=1}} current
- 17:27, 30 April 2024 diff hist +14 m Multiple myeloma, relapsed-refractory →Regimen variant #2 {{#subobject:fc94h1|Variant=1}}
- 13:11, 30 April 2024 diff hist 0 m Soft tissue sarcoma →Doxorubicin monotherapy {{#subobject:826f82|Regimen=1}} current
- 13:07, 30 April 2024 diff hist +1,701 m Soft tissue sarcoma →Doxorubicin monotherapy {{#subobject:826f82|Regimen=1}}
- 12:58, 30 April 2024 diff hist +44 m Soft tissue sarcoma →References
- 11:33, 30 April 2024 diff hist +20 m Soft tissue sarcoma →Cisplatin monotherapy {{#subobject:6e93fa|Regimen=1}}
- 11:31, 30 April 2024 diff hist +19 m Desmoid tumor current
- 11:29, 30 April 2024 diff hist -7 m Desmoid tumor →Nirogacestat monotherapy {{#subobject:f3agdc|Regimen=1}}
- 11:27, 30 April 2024 diff hist +86 m Breast cancer, triple negative current
- 11:05, 30 April 2024 diff hist +2 m Breast cancer, triple negative →References
- 11:04, 30 April 2024 diff hist +25 m Breast cancer, triple negative →Carboplatin & Gemcitabine (GCb) {{#subobject:d46b34|Regimen=1}}
- 11:03, 30 April 2024 diff hist +2 m Breast cancer, triple negative →References
- 11:02, 30 April 2024 diff hist +2 m Breast cancer, triple negative →References
- 11:01, 30 April 2024 diff hist +44 m Breast cancer, triple negative →References
- 11:00, 30 April 2024 diff hist +46 m Breast cancer, triple negative →FEC-D {{#subobject:0cagj9|Regimen=1}}
- 10:58, 30 April 2024 diff hist +5 m Breast cancer, triple negative →Carboplatin & Docetaxel {{#subobject:82336a|Regimen=1}}
- 10:56, 30 April 2024 diff hist +614 m Breast cancer, triple negative →References
- 23:39, 29 April 2024 diff hist +804 m Breast cancer - null regimens →Placebo current
- 23:33, 29 April 2024 diff hist +166 m Tisotumab vedotin (Tivdak) current
- 23:32, 29 April 2024 diff hist +551 m Cervical cancer →Advanced or metastatic disease, subsequent lines of therapy current
- 23:38, 28 April 2024 diff hist +264 m Lutetium Lu 177 dotatate (Lutathera) →History of changes in FDA indication current
- 21:59, 28 April 2024 diff hist +1,125 Low-grade glioma, pediatric →Temozolomide monotherapy {{#subobject:7b66b|Regimen=1}} current
- 21:54, 28 April 2024 diff hist +1,193 N Tovorafenib (Ojemda) Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tovorafenib NCI Drug Dictionary]: An orally available inhibitor of wild-type..." current
- 21:48, 28 April 2024 diff hist +56 m Drug index →T current
- 12:28, 28 April 2024 diff hist +217 m Upper tract urothelial carcinoma current
- 12:27, 28 April 2024 diff hist +1,402 m Upper tract urothelial carcinoma
- 12:25, 28 April 2024 diff hist +521 m Upper tract urothelial carcinoma - null regimens →References current
- 16:49, 27 April 2024 diff hist +213 m Marginal zone lymphoma current
- 16:46, 27 April 2024 diff hist +3 m Marginal zone lymphoma →References
- 15:02, 27 April 2024 diff hist +258 m Marginal zone lymphoma
- 14:57, 27 April 2024 diff hist +531 m Study Groups →Main table current
- 14:47, 27 April 2024 diff hist -326 m Study Groups →Pediatrics-focused